Here are the highlights.
Star Entertainment share price gains alongside balance sheet
Net revenue of $866 million, down 14.6% year on year
Earnings before interest, taxes, depreciation and amortisation (EBITDA) before significant items of $114 million, down 43.1% from 1H FY 2023
Net profit after tax (NPAT) before significant items of $25 million, down 42.7% year on year
Significant items after tax a loss of $15.9 million, compared to a loss of $1.307 billion in the prior corresponding period
Net cash position of $171 million as at 31 December, up from a net debt position of $596 million as at 30 June
- Forums
- ASX - By Stock
- SGR
- Ann: Media Release - H1 FY24 Financial Results
Ann: Media Release - H1 FY24 Financial Results, page-2
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
Add SGR (ASX) to my watchlist
|
|||||
Last
51.0¢ |
Change
0.010(2.00%) |
Mkt cap ! $1.463B |
Open | High | Low | Value | Volume |
50.5¢ | 51.0¢ | 50.0¢ | $4.173M | 8.244M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 864292 | 50.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
51.0¢ | 271534 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 113479 | 0.505 |
7 | 313007 | 0.500 |
9 | 169824 | 0.495 |
11 | 287629 | 0.490 |
12 | 570374 | 0.485 |
Price($) | Vol. | No. |
---|---|---|
0.510 | 220582 | 6 |
0.515 | 751301 | 13 |
0.520 | 1637165 | 29 |
0.525 | 225503 | 7 |
0.530 | 231053 | 11 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
SGR (ASX) Chart |